EU approves type 2 diabetes drug GLP-1 receptor agonist Rybelsus
-
Last Update: 2020-06-25
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Novo Nordisk today announced that the European Medicines Agency (EMA) has approved the sale of the company's oral GLP-1 receptor agonisant Rybelsus (semaglutide) to help control blood sugar in people with type 2 diabetesNovo Nordisk said it expected rybelsus to be introduced in the first EU countries in the second half of 2020The approval is based on the latest data from the PIONEER clinical trial, which recruited 9,543 participants to study the effectiveness and safety of Rybelsus, the DPP-4 inhibitor Januvia, the SGLT2 inhibitor Jardiance, and the sub-skin GLP-1 analogy VictozaSeptember 2019, Rybelsus was approved by the FDA for type 2 diabetes, and in early 2020, Rybelsus received positive reviews from the European Medicines Agency (EMA) Human Medicines Committee (CHMP)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
